Login / Signup

Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access.

Eunjin HongMarco ZampoliPaul M Beringer
Published in: Clinical pharmacology and therapeutics (2024)
Keyphrases
  • cystic fibrosis
  • pseudomonas aeruginosa
  • lung function
  • affordable care act
  • healthcare